PHARMACYCLICS INC Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 67 rows in 2014. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2014-11-13: Reporting owner Fardis Maria; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2014-11-13: Reporting owner Soni Manmeet Singh; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2014-11-12: Reporting owner Zanganeh Maky; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2014-11-10: Reporting owner Zanganeh Maky; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2014-11-13 | Fardis Maria Officer (Chief of Oncology Ops & Allian) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 44,500 owned after | $6.84 exercise price | 2014-11-17 | |
| 2014-11-13 | Soni Manmeet Singh Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,000 19,000 owned after | $61.60 exercise price | 2014-11-17 | |
| 2014-11-12 | Zanganeh Maky Officer (Chief Operating Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,931 144,069 owned after | $7.19 exercise price | 2014-11-12 | |
| 2014-11-10 | Zanganeh Maky Officer (Chief Operating Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −23,000 48,219 owned after | $2.30 exercise price | 2014-11-12 | |
| 2014-11-10 | Love Richard B Officer (General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 64,000 owned after | $32.38 exercise price | 2014-11-10 | |
| 2014-11-07 | Zanganeh Maky Officer (Chief Operating Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,551 71,219 owned after | $2.30 exercise price | 2014-11-12 | |
| 2014-11-07 | Fardis Maria Officer (Chief of Oncology Ops & Allian) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 47,500 owned after | $6.84 exercise price | 2014-11-10 | |
| 2014-10-01 | Booth Robert F. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +314 314 owned after | $115.80 exercise price | 2014-10-03 | |
| 2014-10-01 | van den Broek Richard Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +338 338 owned after | $115.80 exercise price | 2014-10-03 | |
| 2014-10-01 | Clark Kenneth A Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +284 284 owned after | $115.80 exercise price | 2014-10-03 | |
| 2014-10-01 | Mehta Minesh Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +314 314 owned after | $115.80 exercise price | 2014-10-03 | |
| 2014-10-01 | Smith David Duane Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +308 308 owned after | $115.80 exercise price | 2014-10-03 | |
| 2014-10-01 | HALVORSON ERIC H Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +327 327 owned after | $115.80 exercise price | 2014-10-03 | |
| 2014-09-04 | Zanganeh Maky Officer (Chief Operating Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 72,770 owned after | $2.30 exercise price | 2014-09-04 | |
| 2014-09-03 | Zanganeh Maky Officer (Chief Operating Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,000 77,770 owned after | $2.30 exercise price | 2014-09-04 | |
| 2014-08-27 | Love Richard B Officer (General Counsel) | 4 | stock option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 65,500 owned after | $32.38 exercise price | 2014-08-28 | |
| 2014-08-21 | Tan Heow Officer (Chief Quality&Tech Operations) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | +2,196 76,304 owned after | $27.05 exercise price | 2014-08-22 | |
| 2014-08-18 | Tomasello Shawn Officer (Chief Commercial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $121.89 exercise price | 2014-08-19 | |
| 2014-08-13 | Fardis Maria Officer (Chief of Oncology Ops & Allian) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,000 51,393 owned after | $6.84 exercise price | 2014-08-15 | |
| 2014-08-07 | McGreivy Jesse Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,645 15,313 owned after | $25.33 exercise price | 2014-08-07 | |
| 2014-08-07 | McGreivy Jesse Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −11,667 23,333 owned after | $61.60 exercise price | 2014-08-07 | |
| 2014-07-07 | Bari Samina Officer (SVP, Corp Communications) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $96.91 exercise price | 2014-07-08 | |
| 2014-07-01 | van den Broek Richard Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +456 456 owned after | $89.58 exercise price | 2014-07-02 | |
| 2014-07-01 | Smith David Duane Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +416 416 owned after | $89.58 exercise price | 2014-07-02 | |
| 2014-07-01 | Mehta Minesh Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +407 407 owned after | $89.58 exercise price | 2014-07-02 | |
| 2014-07-01 | HALVORSON ERIC H Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +440 440 owned after | $89.58 exercise price | 2014-07-02 | |
| 2014-07-01 | Clark Kenneth A Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +367 367 owned after | $89.58 exercise price | 2014-07-02 | |
| 2014-07-01 | Booth Robert F. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +424 424 owned after | $89.58 exercise price | 2014-07-02 | |
| 2014-05-09 | van den Broek Richard Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,750 3,750 owned after | $95.08 exercise price | 2014-05-12 | |
| 2014-05-09 | Smith David Duane Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,750 3,750 owned after | $95.08 exercise price | 2014-05-12 | |
| 2014-05-09 | Mehta Minesh Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,750 3,750 owned after | $95.08 exercise price | 2014-05-12 | |
| 2014-05-09 | HALVORSON ERIC H Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,750 3,750 owned after | $95.08 exercise price | 2014-05-12 | |
| 2014-05-09 | Clark Kenneth A Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,750 3,750 owned after | $95.08 exercise price | 2014-05-12 | |
| 2014-05-09 | Booth Robert F. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,750 3,750 owned after | $95.08 exercise price | 2014-05-12 | |
| 2014-05-08 | Sjovall Boultbee Paula S Officer (EVP, Sales and Marketing) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,710 159,790 owned after | $25.94 exercise price | 2014-05-08 | |
| 2014-04-29 | Sjovall Boultbee Paula S Officer (EVP, Sales and Marketing) | 4 | Stock Option (Right to Buy) Derivative · Indirect · By Spouse | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,332 32,668 owned after | $57.16 exercise price | 2014-05-01 | |
| 2014-04-02 | Zanganeh Maky Officer (Chief Operating Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $102.22 exercise price | 2014-04-04 | |
| 2014-04-02 | McGreivy Jesse Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $102.22 exercise price | 2014-04-04 | |
| 2014-04-02 | Tan Heow Officer (Chief Quality&Tech Operations) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $102.22 exercise price | 2014-04-04 | |
| 2014-04-02 | Love Richard B Officer (General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +25,000 25,000 owned after | $102.22 exercise price | 2014-04-04 | |
| 2014-04-02 | Erdtmann Rainer M Officer (Sr. VP, IR and Admin) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +25,000 25,000 owned after | $102.22 exercise price | 2014-04-04 | |
| 2014-04-02 | Soni Manmeet Singh Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $102.22 exercise price | 2014-04-04 | |
| 2014-04-02 | Fardis Maria Officer (Chief of Oncology Ops & Allian) | 4 | Stock OPtion (right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $102.22 exercise price | 2014-04-04 | |
| 2014-04-01 | Mehta Minesh Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +157 157 owned after | $107.42 exercise price | 2014-04-03 | |
| 2014-04-01 | Smith David Duane Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +233 233 owned after | $107.42 exercise price | 2014-04-03 | |
| 2014-04-01 | van den Broek Richard Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +280 280 owned after | $107.42 exercise price | 2014-04-03 | |
| 2014-04-01 | HALVORSON ERIC H Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +267 267 owned after | $107.42 exercise price | 2014-04-03 | |
| 2014-04-01 | Clark Kenneth A Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +194 194 owned after | $107.42 exercise price | 2014-04-03 | |
| 2014-04-01 | Booth Robert F. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +240 240 owned after | $107.42 exercise price | 2014-04-03 | |
| 2014-03-20 | Sjovall Boultbee Paula S Officer (EVP, Sales and Marketing) | 4 | Stock Option (Right to Buy) Derivative · Indirect · By Spouse | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +400 400 owned after | $120.49 exercise price | 2014-05-01 | |
| 2014-03-17 holding as of filing | Outten Matthew Officer (VP, Commercial Operations) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $70.70 exercise price | 2014-03-17 | ||
| 2014-03-05 | Fardis Maria Officer (Chief of Oncology Ops & Allian) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 56,500 owned after | $6.84 exercise price | 2014-03-07 | |
| 2014-03-05 | Hemmi Gregory Officer (Sr. VP Chemical Operations) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 88,515 owned after | $0.86 exercise price | 2014-03-06 | |
| 2014-03-05 | McGreivy Jesse Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,563 18,958 owned after | $25.00 exercise price | 2014-03-06 | |
| 2014-03-05 | Sjovall Boultbee Paula S Officer (EVP, Sales and Marketing) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,253 180,000 owned after | $25.94 exercise price | 2014-03-06 | |
| 2014-03-04 | Sjovall Boultbee Paula S Officer (EVP, Sales and Marketing) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,747 186,253 owned after | $25.94 exercise price | 2014-03-06 | |
| 2014-03-04 | HALVORSON ERIC H Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 12,500 owned after | $14.26 exercise price | 2014-03-06 | |
| 2014-03-04 | HALVORSON ERIC H Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −148 0 owned after | $15.02 exercise price | 2014-03-06 | |
| 2014-03-04 | HALVORSON ERIC H Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −824 0 owned after | $28.47 exercise price | 2014-03-06 | |
| 2014-03-04 | Chang Betty Y Officer (VP, Research/Biology) | 4 | Stoxk Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −11,875 3,125 owned after | $7.69 | 2014-03-05 | |
| 2014-03-04 | Chang Betty Y Officer (VP, Research/Biology) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,625 4,375 owned after | $15.63 | 2014-03-05 | |
| 2014-02-28 | Soni Manmeet Singh Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,000 8,000 owned after | $138.66 exercise price | 2014-02-28 | |
| 2014-01-02 | van den Broek Richard Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +264 264 owned after | $108.44 exercise price | 2014-01-06 | |
| 2014-01-02 | Smith David Duane Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +217 217 owned after | $108.44 exercise price | 2014-01-06 | |
| 2014-01-02 | HALVORSON ERIC H Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +252 252 owned after | $108.44 exercise price | 2014-01-06 | |
| 2014-01-02 | Mehta Minesh Director | 4 | Stock Option (Right to But) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +238 238 owned after | $108.44 exercise price | 2014-01-03 | |
| 2014-01-02 | Clark Kenneth A Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +192 192 owned after | $108.44 exercise price | 2014-01-03 |